NORROY BioScience Secures FDA Fast Track for Renal Cancer Imaging Agent

The investigational agent targets carbonic anhydrase IX to help clinicians characterize indeterminate renal masses identified through traditional CT or MRI scans. By distinguishing clear cell renal cell carcinoma—which accounts for up to 80% of kidney cancer cases—from benign lesions, the technology aims to address a significant gap in diagnostic accuracy. The FDA designations provide a streamlined regulatory path, including more frequent agency interactions and potential eligibility for rolling review of a New Drug Application.

Founder and CEO Peng Fang noted that preliminary clinical results have already demonstrated the agent's potential to improve patient management. The company plans to showcase additional data at the 2026 EANM Annual Congress and is preparing to launch Phase I clinical trials across both China and the United States. While these regulatory milestones signal confidence in the program, the product remains under investigation and has not yet received final marketing approval.